Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
32.00    -0.75 (-2.29%)
Bid:
31.00
Ask:
33.00
Spread: 2.00 (6.452%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Replacement: Trading update

17 Mar 2017 18:25

RNS Number : 8736Z
Ilika plc
17 March 2017
 

A number of non material typographical changes have been made to the 'Trading update' announcement released on 17 March 2017 at 07.00 under RNS No 7455Z.

 

The changes are identified with an asterisk (*).

 

The full amended text is shown below.

 

17 March 2017

Ilika plc

("Ilika" or the "Company")

 

Trading update

 

Ilika (AIM: IKA), a pioneer in materials innovation and solid-state battery technology, announces the following update on trading.

 

Revenue update

Since its last trading update in November 2016, the Company has announced four significant commercial deals, which are resulting in a strong ramp-up of revenue relative to 2015/16 and which will continue to support revenue growth into 2017/18. We expect to start 2017/18 with a record level of revenue commitments amounting to around £1.8m.

 

Ilika's stated business aim is to add licensing revenue to the development revenue it currently generates. While levels of interest are encouraging, predicting the timing of when these licenses will generate revenue remains a significant forecasting challenge for the Company. Given our proximity to the end of Ilika's current financial year and the duration of negotiations with OEM potential licensees, it seems increasingly likely that revenue from licensing may first have an impact in 2017/18.

 

Stereax roadmap update

Ilika has continued to develop its Stereax intellectual property in accordance with its roadmap, which it updates in line with feedback from its pipeline of development partners. Earlier this month, Ilika confirmed that it had secured a partnership with a bioelectronics company*, focused on optimising the Stereax platform for use in miniature medical implants*. Bioelectronics is a rapidly developing market with large opportunities that match the unique benefits that Stereax offers. Stereax's high volumetric energy density, manufacturability at mm-scale and the ability to deliver pulses of power are ideal for such devices. *

 

Towards the end of last year, Ilika announced the start of a funded collaborative project with Sharp Laboratories of Europe ("Sharp") to create a device consisting of an integrated StereaxTM solid-state battery and a photovoltaic panel, offering an autonomous energy harvesting device for wireless components. The initial concept was designed to address opportunities in automotive and wearables, but publicity around the project has also attracted interest from consumer goods companies looking for innovative ways to promote their products in retail outlets.

 

The next product milestone on Ilika's Stereax roadmap is its industrial battery, code-named Endeavour, which will be able to operate in an extended temperature range covering -40 to 150 degree Celsius. This battery is designed to meet the requirements of Industrial IoT, sometimes called Industry 4.0. A discussion of applications is covered in our recently-posted video featuring Meggitt and IBM which can be found here - http://www.ilika.com/news/videos.

 

Materials development programmes

While the Company is deploying most of its operational and commercial resources on Stereax activities, it has also seen an increase in materials development programmes on its high throughput technology platform. Last month Ilika announced that it had received notification of a renewal of the commercial relationship it has with Seagate to develop photonic materials and processes for Hard Disk Drive ("HDD") technology.

 

Ilika has also recently announced the renewal and strengthening of its long-standing relationship with Toyota. This has been triggered by the award of a contract by the Toyota Research Institute in the USA, which was founded at the end of 2015 with an initial focus on artificial intelligence, robotics and materials innovation.

 

The Company will announce a more detailed update on the outturn for 2016/17 in May prior to issuing its full year results in July.

 

Graeme Purdy, CEO of Ilika, commented: "We are continuing to see a reinforcement of our customer relationships, with long-standing partnerships with companies like Toyota and Seagate being further cemented. It's also great to see the upturn in revenues relative to last year allowing us to start 2017/18 with such a strong order book. The number of potential licensees, their level of interest and the diversity of applications is giving us growing confidence in our licensing model."

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan/ Paul Gillam (Corporate Adviser)

 

James Black/ Michael Burke (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Paul Cornelius

Mob: 07866 384 707

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDXCBBBGRR
Date   Source Headline
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
31st May 20242:29 pmRNSHolding(s) in Company
29th May 202411:52 amRNSResults of General Meeting Open Offer and TVR
22nd May 20247:00 amRNSKey Goliath Technology Validation Milestone
16th May 20247:00 amRNSTrading Update, Notice of Results & Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.